SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 12, 2024 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, according to a study published online Dec. 11 in the New England Journal of Medicine to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.

Komal L. Jhaveri, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a phase 3 trial enrolling 874 patients with ER-positive, HER2-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 inhibitor. Patients were randomly assigned to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib (331, 330, and 213 patients, respectively). Investigator-assessed progression-free survival was compared for imlunestrant versus standard therapy among 256 patients with ESR1 mutations and among all patients.

The researchers found that among the 256 patients with ESR1 mutations, median progression-free survival was 5.5 and 3.8 months with imlunestrant and standard therapy, respectively. The corresponding estimated restricted mean survival time was 7.9 and 5.4 months at 19.4 months. In the overall population, median progression-free survival was 5.6 and 5.5 months with imlunestrant and standard therapy, respectively (hazard ratio for progression or death, 0.87; 95 percent confidence interval, 0.72 to 1.04; P = 0.12). Comparing imlunestrant-abemaciclib with imlunestrant, median progression-free survival was 9.4 and 5.5 months, respectively (hazard ratio for progression or death, 0.57; 95 percent confidence interval, 0.44 to 0.73; P < 0.001).

"Imlunestrant therapy significantly improved progression-free survival over standard therapy among patients with ESR1 mutations," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures imlunestrant and funded the study.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-13 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords